Endometriosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The endometriosis market size across the 7MM was valued at $1.05 billion in 2020 and is expected to achieve a CAGR of more than 9% during 2020-2030. Women with endometriosis develop tissue that looks and acts like endometrial tissue outside of the uterus, usually on other reproductive organs inside the pelvis or in the abdominal cavity.
Risk factors for endometriosis include a family history of endometriosis, early age of menarche, short menstrual cycles, long duration of menstrual flow, heavy bleeding during menses, delayed childbearing, and defects in the uterus or fallopian tubes. Endometriosis typically develops on pelvic structures including the rectovaginal septum, bladder, ovaries, and fallopian tubes. However, it may also be found in more distant regions including the kidneys, bowels, intestines, lungs, and sometimes in the brain.
The endometriosis market research report provides an overview of endometriosis, including epidemiology, disease etiology, and management.
Endometriosis Market Outlook
To gain more information about the endometriosis market forecast, download a free report sample
Endometriosis Market Drivers
Some of the major drivers of growth in the endometriosis market across the 7MM over the forecast period include improvements in noninvasive diagnostic methods, such as the utilization of biomarkers, the launch of Myovant’s Ryeqo (relugolix/estradiol/norethisterone acetate), and global launch of quinagolide, an endometriosis therapy that, unlike marketed therapies, does not interfere with ovulation.
Endometriosis Market Segmentation by Class of Drugs
The key classes of drugs in the US endometriosis market are GnRH agonists, Progestins, Estrogen antagonists, off-label, GnRH antagonists, and Dopamine D2 receptor antagonist. GnRH agonists accounted for the largest patient share in the US endometriosis market. The growth in US sales will mainly be driven by the uptake of the relugolix combination tablet, Myfembree, and Yselty (linzagolix), which will in turn stimulate sales of AbbVie’s Orilissa as GnRH antagonists populate the endometriosis market.
Endometriosis Market Analysis, by Class of Drugs in the US
For more endometriosis classes of drugs insights, download a free report sample
Endometriosis Market - Competitive Landscape
Some of the leading players in the endometriosis market are AbbVie, Ipsen, Neurocrine Biosciences, DebioPharm Group, Ferring Pharmaceuticals, AstraZeneca, Mitsubishi Tanabe, Pfizer, Kissei Pharmaceuticals, Bayer, Gedeon Richter, and Evotec.
Endometriosis Market Report Overview
Market Size (2020) | $1.05 billion |
CAGR (2020 – 2030) | >9% |
Key Class of Drugs | GnRH Agonists, Progestins, Estrogen Antagonists, Off-Label, GnRH Antagonists, and Dopamine D2 Receptor Antagonist |
Leading Players | AbbVie, Ipsen, Neurocrine Biosciences, DebioPharm Group, Ferring Pharmaceuticals, AstraZeneca, Mitsubishi Tanabe, Pfizer, Kissei Pharmaceuticals, Bayer, Gedeon Richter, and Evotec |
Scope
This report provides:
- Topline endometriosis drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), the annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players, and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global endometriosis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global endometriosis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global endometriosis therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Ipsen
Neurocrine Biosciences
DebioPharm Group
Ferring Pharmaceuticals
AstraZeneca
Mitsubishi Tanabe
Pfizer
Kissei Pharmaceuticals
Bayer
Gedeon Richter
Evotec
Myovant Sciences
ObsEva
Astellas
Takeda
Nippon Shinyaku
Teva
Table of Contents
Table
Figures
Frequently asked questions
-
What was the endometriosis market size in 2020?
The endometriosis market size was valued at $1.05 billion in 2020.
-
What is the endometriosis market growth rate?
The endometriosis market is expected to achieve a CAGR of more than 9% during 2020-2030.
-
What are the key classes of drugs in the US endometriosis market?
The key classes of drugs in the US endometriosis market are GnRH agonists, Progestins, Estrogen antagonists, off-label, GnRH antagonists, and Dopamine D2 receptor antagonist.
-
Who are the leading players in the endometriosis market?
Some of the leading players in the endometriosis market are AbbVie, Ipsen, Neurocrine Biosciences, DebioPharm Group, Ferring Pharmaceuticals, AstraZeneca, Mitsubishi Tanabe, Pfizer, Kissei Pharmaceuticals, Bayer, Gedeon Richter, and Evotec.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.